
Opinion|Videos|January 29, 2025
Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System
Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Could you discuss the key outcomes from the ARCHWAY trial for PDS?
- The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
From AI to injury patterns: Insights from emerging ophthalmic research
2
FLORetina 2025: Reframing retinal disease through the lens of choroidal health
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5












































